Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 9/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15766084 | 0.88 | PRKCI (0.41) | PRKCIPPARASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15766176 | 0.79 | CCR6 (0.42) | PPARASMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL3620698 | 0.73 | MAPT (0.47) | PPARASMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL10611217 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL15766377 | 0.71 | DHODH (0.40) | PPARASMN1; SMN2HPGDKDM4ECCR6 | |
| SCHEMBL15766108 | 0.71 | MEN1 (0.43) | PPARASMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL14975439 | 0.69 | PRKCI (0.47) | PRKCIMAPK1MCL1 | |
| SCHEMBL22700523 | 0.68 | MEN1 (0.42) | SMN1; SMN2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL22006582 | 0.68 | PRKCI (0.43) | PRKCISMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL14986635 | 0.68 | PRKCI (0.62) | PRKCISMN1; SMN2MAPK1MCL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163219-A1 | HCV Protease Inhibitors | CPN1, CTRL, CTSZ | PRKCI 3987/4885PPARA 2493/4885SMN1; SMN2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.